Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients

Brierley, Gemma V.; Priebe, Ilka; Purins, Leanne; Fung, Kim Y. C.; Tabor, Bruce; Lockett, Trevor; Nice, Edouard C.; Gibbs, Peter; Tie, Jeanne; McMurrick, Paul; Moore, James W.; Ruszkiewicz, Andrew; Burgess, Antony W.; Cosgrove, Leah

doi:10.3233/cbm-130345

Cited by 27 publications

(26 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although no association with the CRC stage was detected, which was in accordance with a previous study (16), a significant increase of these rates (P=0.0059 for BDNF and P=0.0457 for NT4/5) was observed in patients who were under psychotropic treatments, in particular for BDNF in patients treated with benzodiazepine (P= 0.0221). As benzodiazepine is able to act on the central nervous system, it is expected to affect the levels of BDNF, as previously demonstrated in patients treated for depression with diazepam (5 mg), or tandospirone (20 mg) or paroxetine (10 mg), versus matched placebo (8).…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients

Sarabi¹,

Perraud²,

Mazouffre³

et al. 2016

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Previous studies have reported the association between brain-derived neurotrophic factor (BDNF) and tumor development in numerous cancers. However, the accurate implication of the two specific ligands of tropomyosin kinase B receptor, BDNF and neurotrophic factor 4 (NT4/5), has not been studied in colorectal cancer (CRC) patients. The present study investigated the significance of serum BDNF and the NT4/5 in association with the intake of psychoactive drugs in CRC patients. Soluble BDNF and NT4 in the serum were assessed by ELISA. Although no correlation of BDNF and NT4 with the CRC stage was identified, a positive correlation was found between NT4 and the intake of psychoactive drugs (P=0.0457). For BDNF, a correlation was found in particular with the intake of benzodiazepine (P= 0.0221). As BDNF and NT4/5 are implicated in the response of psychoactive treatments applied to manage depression, which frequently occurs in cancer patients, they cannot be used as prognostic or diagnostic markers for CRC in these patients. However, high expression of BDNF and NT4 was significantly associated with better survival. Therefore, these NTs may be used as markers for monitoring depression or predicting survival in CRC patients.

show abstract

Section: Discussionsupporting

confidence: 90%

“…To the best of our knowledge, only one study has assessed BDNF in the serum of CRC patients, revealing that it was decreased in patients compared with that in controls and was not associated with the stage of CRC (16). Among other studies, BDNF expression shows a large variation in different cancer types.…”

Section: Introductionmentioning

confidence: 99%

Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients

Sarabi¹,

Perraud²,

Mazouffre³

et al. 2016

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…It has been found BDNF/TrkB are up-regulated in countless types of cancers, such as breast cancer, carcinoid, cervical, colorectal, glioma, liver, lung (6)(7)(8)(9)(10)(11)(12). Some studies even revealed BDNF might be an important prognostic factor for cancers (12,(48)(49)(50). Recently, BDNF/TrkB pathway has been demonstrated to transactivate EGFR, a growth factor receptor commonly up-regulated in many cancers (43,51).…”

Section: Oncogenic Role Of Bdnf In Tumormentioning

confidence: 99%

Targeting the BDNF/TrkB pathway for the treatment of tumors (Review)

Meng

Liu

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Neurotrophins are a family of growth factors that regulate neural survival, development, function and plasticity in the central and the peripheral nervous system. There are four neurotrophins: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and NT-4. Among them, BDNF is the most studied due to its high expression in the brain. Over the past two decades, BDNF and its receptor tropomyosin receptor kinase B (TrkB) have been reported to be upregulated in a wide range of tumors. This activated signal stimulates a series of downstream pathways, including phosphoinositide 3-kinase/protein kinase B, Ras-Raf-mitogen activated protein kinase kinase-extracellular signal-regulated kinases, the phospholipase-C-γ pathway and the transactivation of epidermal growth factor receptor. Activation of these signaling pathways induces oncogenic effects by increasing cancer cell growth, proliferation, survival, migration and epithelial to mesenchymal transition, and decreasing anoikis, relapse and chemotherapeutic sensitivity. The present review summarizes recent findings to discuss the role of BDNF in tumors, the underlying molecular mechanism, targeting Trk receptors for treatment of cancers and its potential risk.

show abstract

“…Przedmiotem wielu badań ostatnich lat jest udział BDNF i jego receptora TrkB w onkogenezie. Po raz pierwszy został on scharakteryzowany w przypadku nowotworów dotyczących ośrodkowego układu nerwowego (OUN), jednak w ostatnich latach wykazano, że związek ten odgrywa także kluczową rolę w patogenezie nowotworów nieneurogennych, w tym raka jelita grubego [5]. extracellular signal regulated kinase (ERK) and serine/threonine protein kinase (Akt) activated by BDNF additionally cause the resistance of cancer cells to cytostatic drugs [6,7,8].…”

Section: Wstępunclassified

“…The participation of BDNF and its TrkB receptor in oncogenesis has been the subject of many studies in recent years. It was first characterised in the case of neoplasms affecting the central nervous system (CNS), but in recent years it has been demonstrated that this compound also plays a key role in the pathogenesis of non-neurogenic neoplasms, including colorectal cancer [5]. The signalling pathways of, e.g.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of neurotrophic growth factor (BDNF) in patients with colorectal cancer during chemotherapy

Olborska

Głogowska-Gruszka

Słomian³

et al. 2019

Ann. Acad. Med. Siles.

View full text Add to dashboard Cite

INTRODUCTION: The brain-derived neurotrophic factor (BDNF) is a protein belonging to neurotrophins that plays a key role in the proper development and functioning of the mammalian central nervous system. Previous studies have focused on assessment of the BDNF concentration in blood serum as a potential biomarker in neurological disorders. Recently, the BDNF signalling pathway has been recognised as a potential target for anticancer drugs, while its receptor (TrkB) as an oncogene in colorectal cancer cells. Despite the significant role in carcinogenesis, there are few studies on BDNF as a biomarker in colorectal cancer. MATERIAL AND METHODS: The study included 25 patients with clinically and histopathologically confirmed colorectal cancer, who were qualified for treatment. Prior to the first administration of chemotherapy, venous blood samples were collected from the patients and the biochemical parameters routinely determined prior to treatment were evaluated. Additionally, the serum BDNF concentration was determined by the immunoenzymatic method in all the patients. RESULTS: The serum BDNF concentration in patients was 50.24 ± 23.37 ng/ml. The BDNF concentration did not differ significantly between women and men. A negative correlation was found between the BDNF and CRP concentration and the BDNF and LDH concentration. The BDNF levels were significantly higher in patients who underwent primary tumour resection before chemotherapy. There was no correlation between the BDNF concentration and age, gender, BMI, CEA marker and liver enzymes in patients with colorectal cancer. There was no correlation between the BDNF concentration and clinical response to the treatment. CONCLUSIONS: BDNF cannot be considered as a prognostic factor in patients with colorectal cancer.

show abstract

Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients

Abstract: The serum levels of BDNF were significantly lower in colorectal cancer patients when compared to a control population, and this did not differ between different Dukes' stages.

Cited by 27 publications

References 24 publications

Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients

Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients

Targeting the BDNF/TrkB pathway for the treatment of tumors (Review)

Prognostic value of neurotrophic growth factor (BDNF) in patients with colorectal cancer during chemotherapy

Contact Info

Product

Resources

About